Project Grant R21AI189420
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia $717,952 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct investigator-initiated biomedical research on Chlamydia trachomatis pathogenesis. The project, initiated February 9, 2026, and extending through January 31, 2031, focuses on identifying and characterizing essential chlamydia-specific factors to advance the development...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $431,750 to the University of California, Irvine under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with a completion date of July 31, 2027. This project grant supports the development of advanced genetic complementation tools for validating virulence determinants in Chlamydia trachomatis, addressing a critical research gap in studying this...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Virginia a Project Grant of $450,766 under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on inter-organelle communication mechanisms during Chlamydia infection. Awarded on August 8, 2025, with completion targeted for July 31, 2027, this project will deliver fundamental research findings addressing how Chlamydia trachomatis—the leading cause...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3.25 million Project Grant to the University of California, Davis under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 25, 2025. This award supports research examining vaccine-mediated cross-protection and transmission dynamics associated with IXCHIQ, the first FDA-licensed live attenuated chikungunya virus (CHIKV) vaccine. The research will evaluate the...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $126,460 to the University of California, Davis under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 21, 2025, with a completion date of July 31, 2027. This award funds research to identify ecological drivers of dysbiosis in the female reproductive tract (FRT), specifically investigating how hormonal and metabolic changes in the vaginal...
- Federal Grant Award Summary Duke University's Office of Research Administration received a $170,753 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 14, 2025, with a completion date of November 30, 2026. This award funds biomedical research designed to elucidate the molecular mechanisms by which Chlamydia trachomatis (CT), the most common sexually transmitted...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $720,021 Project Grant to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 6, 2026, with a completion date of January 31, 2031. This research initiative focuses on developing broadly protective immunization strategies against Group A Streptococcus (Strep A) by designing M protein-based immunogens that elicit...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $431,004 Project Grant to the University of California, Davis under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 18, 2025, with a completion date of June 30, 2027. This award supports biomedical research investigating the mechanistic interplay between human cells and Entamoeba histolytica, a pathogenic amoeba that causes amoebiasis. The research project,...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $439,375 to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 20, 2026, with a completion date of January 31, 2028. This Project Grant supports the development and validation of S protein as a novel vaccine candidate against Group A Streptococcus (GAS), a pathogen responsible for approximately 700 million infections and...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $744,328 to the University of California, Davis on February 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support a five-year project extending through January 31, 2031. The research investigates the role of trogocytosis—a cell-nibbling mechanism—in the pathogenesis of amoebiasis caused by Entamoeba histolytica. The project will deliver scientific research...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded $404,570 to the University of California, Davis under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 13, 2026, with completion targeted for January 31, 2028. This Project Grant supports research aimed at identifying and validating target antigens for Chlamydia trachomatis vaccine development. The research addresses a significant public health need, as C. trachomatis represents the most prevalent sexually transmitted infection in the United States with 1.64 million reported cases in 2022, and untreated infections in women can result in serious reproductive complications including pelvic inflammatory disease, ectopic pregnancy, and infertility. The funded research will deliver scientific outputs through two primary research streams: (1) identification and validation of Chlamydia-specific antigens recognized by protective circulating memory and tissue-resident memory CD4 T cells using a new screening approach, and (2) evaluation of messenger RNA (mRNA) vaccine efficacy in providing protective immunity against C. trachomatis in mouse models. Successful completion of these studies is expected to establish a foundational platform for vaccine development against this neglected disease and advance reproductive health protection for affected populations in the United States.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $404.6k | 2/12/26 |